Study drug B001 for neuromyelitis optic spectrum disorder attacks
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have NMOSD confirmed by 2015 criteria and you test positive for anti-AQP4 antibodies
- You had at least one documented relapse/flare in the past 12 months
- Your disability score (EDSS) is between 0 and 7.5 at screening
- You are age 18 to 70 when you sign consent
- You have not taken certain NMOSD/MS relapse-prevention or immune-related medicines recently (timing limits apply)
- You do not have recent serious infection, pregnancy/breastfeeding, active hepatitis B/C, active tuberculosis, or dangerous lab abnormalities
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called efgartigimod for people having a sudden worsening of NMOSD symptoms. It targets a protein to reduce attack severity and is given alongside standard care.
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
This early-stage trial tests a new injection called KSVCBD to treat neuromyelitis optica spectrum disorder (NMOSD), a rare disease where the immune system damages the optic nerve and spinal cord. The study will examine whether this treatment is safe and helps reduce relapses in patients with a specific antibody marker.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
Hear when a new NMO Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.